Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS) (BIO_ALS-01)

This study has been completed.

Sponsor:

ClinicalTrials.gov Identifier:

NCT00677768

First Posted: May 14, 2008

Last Update Posted: June 3, 2016

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

Collaborators:

ALS Association

ALS Therapy Alliance

National Institutes of Health (NIH)

National Institute of Neurological Disorders and Stroke (NINDS)

Information provided by (Responsible Party):

James D. Berry MD, Massachusetts General Hospital

Purpose

The purpose of this study is to collect 650 blood and 300 cerebrospinal fluid (CSF) samples from people with amyotrophic lateral sclerosis (ALS), pure lower or upper motor neuron diseases, as well as other neurodegenerative diseases and from people with no neurological disorder. Through comparison of these samples, the researchers hope to learn more about the underlying cause of ALS, as well as find unique biological markers, which could be used to diagnose ALS and monitor disease progression.

Additionally, up to 600 blood samples will be collected for a sub-study for DNA analysis. Studying components of the blood, such as DNA, may help us understand what happens when genes function abnormally and how it might be related to disease.

Condition	Intervention
Amyotrophic Lateral Sclerosis Lou Gehrig's Disease Primary Lateral Sclerosis Nervous System Diseases Hereditary Spastic Paraparesis	Other: No intervention


Study Type:	Observational
Study Design:	Observational Model: Case Control Time Perspective: Prospective
Official Title:	A Multicenter Study for the Validation of ALS Biomarkers

Resource links provided by NLM:

Genetics Home Reference related topics: amyotrophic lateral sclerosis juvenile primary lateral sclerosis

MedlinePlus related topics: Amyotrophic Lateral Sclerosis

Genetic and Rare Diseases Information Center resources: Amyotrophic Lateral Sclerosis Primary Lateral Sclerosis Spastic Paraparesis

U.S. FDA Resources

Further study details as provided by James D. Berry MD, Massachusetts General Hospital:

Primary Outcome Measures:

ALS Functional Rating Scale (ALSFRS-R) [ Time Frame: Every 6 months ]
The ALSFRS-R is a quickly administered (5 min) ordinal rating scale used to determine a subject's assessment of their capability and independence in 12 functional activities. There are 12 questions, graded by the subject 0-4 (4 is normal). Score of 0 (worst) to 48 (best). Reflects speech and swallowing, fine motor skills, large motor skills, and breathing.

Biospecimen Retention: Samples With DNA

650 blood samples (plasma and serum)will be collected from four groups: ALS volunteers diagnosed with ALS, volunteers with pure lower or pure upper motor neuron diseases, volunteers with other neurological diseases and healthy control volunteers.

300 cerebrospinal fluid (CSF) samples will be collected from all four groups: ALS volunteers diagnosed with ALS, volunteers with pure lower or pure upper motor neuron diseases, volunteers with other neurological diseases and healthy control volunteers.

Up to 600 DNA samples will also be collected from all 4 groups: ALS volunteers diagnosed with ALS, volunteers with pure lower or pure upper motor neuron diseases, volunteers with other neurological diseases and healthy control volunteers.


Enrollment:	475
Study Start Date:	April 2008
Study Completion Date:	November 2015
Primary Completion Date:	November 2015 (Final data collection date for primary outcome measure)

Groups/Cohorts	Assigned Interventions
Early ALS	Other: No intervention Sample collection
Suspected ALS	Other: No intervention Sample collection
Disease Mimics of ALS	Other: No intervention Sample collection
Healthy Controls	Other: No intervention Sample collection

Detailed Description:

Researchers tested what changes happen in volunteers with ALS that can be seen in the blood and what changes are unique to ALS and are different from those found in healthy volunteers and volunteers with neurological diseases other than ALS. These changes are called biomarkers. Biomarkers for ALS have been found in blood collected in earlier phases of this study. Biomarkers are non-genetic elements in your blood that may help to make diagnosing ALS easier. In the next phase, comparison of these changes in the blood of volunteers with ALS and without ALS will be used to confirm these biomarkers and to develop a tool to diagnose and monitor progression of ALS.

Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	30 Years to 80 Years (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

Volunteers will be invited to participate in this study by their neurologists either in clinic or at a regular scheduled appointment visit.

Criteria

ALS Volunteers

Inclusion Criteria:
- Diagnosis of possible (excluding volunteers with UMN signs ONLY), probable, probable-laboratory supported, or definite ALS, either sporadic or familial according to revised El Escorial criteria
- Disease duration of less than or equal to two years from symptom onset
- Age 30-80 years at the time of disease onset
- Ability to provide informed consent
- Ability to comply with study procedures
- Medically safe to have lumbar puncture (lumbar puncture volunteers only)
Exclusion Criteria:
- Clinical evidence of chronic liver or renal failure
- Presence of a bleeding disorder, problems with CSF pressure, allergy to local anesthetics, or a topical or other skin infection at the LP site (lumbar puncture volunteers only)
- Use of any anti-platelet or anticoagulant drugs, such as plavix, aggrenox, ticlid, warfarin or coumadin (lumbar puncture volunteers only)
Suspected ALS (PMND) Volunteers

Inclusion Criteria:
- Diagnosis of suspected ALS defined as presence of UMN or LMN signs alone and the diagnosis of Clinically Probably Laboratory-Supported ALS CANNOT be proven by evidence in clinical grounds in conjunction with electrodiagnostic, neurophysiologic, neuroimaging or clinically laboratory studies
- Disease duration of less than or equal to four years from symptom onset
- Age 30-80 years at time of disease onset
- Ability to provide informed consent
- Ability to comply with study procedures
- Medically safe to have lumbar puncture (lumbar puncture volunteers only)
Exclusion Criteria:
- Clinical evidence of chronic liver or renal failure
- Genetically confirmed diagnosis of hereditary spastic paraparesis or spinal motor atrophy (SMA) disease
- Presence of a bleeding disorder, problems with CSF pressure, allergy to local anesthetics, or a topical or other skin infection at the LP site (lumbar puncture volunteers only)
- Use of any anti-platelet or anticoagulant drugs, such as plavix, aggrenox, ticlid, warfarin or coumadin (lumbar puncture volunteers only)
Neurological Disease Mimic Volunteers

Inclusion Criteria:

Diagnosis of one of the following:

Pure Lower Motor Neuron Disease (LMND) mimics:
- Multi-focal motor neuropathy
- Autoimmune motor neuropathy
- Cervical or lumbosacral radiculopathies
Peripheral mononeuropathies:
- Ulnar neuropathy
- Carpal tunnel syndrome/median neuropathy
- Peroneal neuropathy
- Sciatic neuropathy
- Spinal muscular atrophy
- Spinobulbar muscular atrophy (Kennedy's disease)
- Charcot Marie-Tooth Disease (CMT)
Pure Upper Motor Neuron Disease (UMND) mimics:
- Cervical myelopathy
- Multiple sclerosis
- Hereditary spastic paraparesis
- Age 30-80 years
- Ability to provide informed consent
- Ability to comply with study procedures
- Medically safe to have lumbar puncture (lumbar puncture volunteers only)
Exclusion Criteria:
- Diagnosis of suspected, possible, probable or definite ALS either sporadic or familial
- Presence of positive family history of ALS
- Clinical evidence of chronic renal or liver failure
- Presence of a bleeding disorder, problems with CSF pressure, allergy to local anesthetics, or a topical or other skin infection at the LP site (lumbar puncture volunteers only)
- Use of any anti-platelet or anticoagulant drugs, such as plavix, aggrenox, ticlid, warfarin or coumadin (lumbar puncture volunteers only)
Healthy Control Volunteers Inclusion Criteria
- Absence of a known neurological disorder.
- Age 30 - 80 years.
- Ability to provide informed consent.
- Ability to comply with study procedures.
- Medically safe to have lumbar puncture.

Exclusion Criteria:

History of ALS, myopathy, neuropathy, ALS mimic disorder or other neurodegenerative disease.
Presence of positive family history of ALS.
Clinical evidence of chronic liver or renal failure.
Presence of bleeding disorder, problems with CSF pressure, allergy to local anesthetics, or a topical or other skin infection at the LP site (LP research volunteers only).
Research participant must not be taking anti-platelet or anticoagulant drugs, such as plavix, aggrenox, ticlid, warfarin or coumadin (LP research volunteers only).

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00677768

Show 30 Study Locations

Sponsors and Collaborators

Massachusetts General Hospital

ALS Association

ALS Therapy Alliance

National Institutes of Health (NIH)

National Institute of Neurological Disorders and Stroke (NINDS)

Investigators


Principal Investigator:	James D. Berry, MD, MPH	Massachusetts General Hospital

More Information

Additional Information:

ALS Association Website This link exits the ClinicalTrials.gov site

NEALS ALS Consortium This link exits the ClinicalTrials.gov site


Responsible Party:	James D. Berry MD, Principal Investigator, Massachusetts General Hospital
ClinicalTrials.gov Identifier:	NCT00677768 History of Changes
Other Study ID Numbers:	BIO_ALS-01 5RC1NS068179-02 ( U.S. NIH Grant/Contract )
First Submitted:	May 9, 2008
First Posted:	May 14, 2008
Last Update Posted:	June 3, 2016
Last Verified:	June 2016

Keywords provided by James D. Berry MD, Massachusetts General Hospital:


Biomarkers Plasma Cerebrospinal Fluid DNA Serum

Additional relevant MeSH terms:


Sclerosis Motor Neuron Disease Amyotrophic Lateral Sclerosis Nervous System Diseases Paraparesis Paraparesis, Spastic Pathologic Processes Neurodegenerative Diseases Neuromuscular Diseases	Spinal Cord Diseases Central Nervous System Diseases TDP-43 Proteinopathies Proteostasis Deficiencies Metabolic Diseases Paresis Neurologic Manifestations Signs and Symptoms

To Top